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Objective: Non-alcoholic steatohepatitis (NASH) is characterized by a robust pro-inflammatory component at both hepatic and systemic levels
together with a disease-specific gut microbiome signature. Protein tyrosine phosphatase 1 B (PTP1B) plays distinct roles in non-immune and
immune cells, in the latter inhibiting pro-inflammatory signaling cascades. In this study, we have explored the role of PTP1B in the composition of
gut microbiota and gut barrier dynamics in methionine and choline-deficient (MCD) diet-induced NASH in mice.
Methods: Gut features and barrier permeability were characterized in wild-type (PTP1B WT) and PTP1B-deficient knockout (PTP1B KO) mice fed
a chow or methionine/choline-deficient (MCD) diet for 4 weeks. The impact of inflammation was studied in intestinal epithelial and enter-
oendocrine cells. The secretion of GLP-1 was evaluated in primary colonic cultures and plasma of mice.
Results: We found that a shift in the gut microbiota shape, disruption of gut barrier function, higher levels of serum bile acids, and decreased
circulating glucagon-like peptide (GLP)-1 are features during NASH. Surprisingly, despite the pro-inflammatory phenotype of global PTP1B-
deficient mice, they were partly protected against the alterations in gut microbiota composition during NASH and presented better gut barrier
integrity and less permeability under this pathological condition. These effects concurred with higher colonic mucosal inflammation, decreased
serum bile acids, and protection against the decrease in circulating GLP-1 levels during NASH compared with their WT counterparts together with
increased expression of GLP-2-sensitive genes in the gut. At the molecular level, stimulation of enteroendocrine STC-1 cells with a pro-
inflammatory conditioned medium (CM) from lipopolysaccharide (LPS)-stimulated macrophages triggered pro-inflammatory signaling cas-
cades that were further exacerbated by a PTP1B inhibitor. Likewise, the pro-inflammatory CM induced GLP-1 secretion in primary colonic
cultures, an effect augmented by PTP1B inhibition.
Conclusion: Altogether our results have unraveled a potential role of PTP1B in the guteliver axis during NASH, likely mediated by increased
sensitivity to GLPs, with potential therapeutic value.
 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic
hepatic disease in Western countries and is considered the hepatic
manifestation of metabolic syndrome [1]. NAFLD is characterized by
the accumulation of different lipid species within the hepatocyte that,
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that protect hepatocytes from fatty acid-mediated lipotoxicity become
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Original Articlehepatocellular carcinoma (7%) [2]. NAFLD represents an important
public health problem due the increased incidence of metabolic syn-
drome worldwide [3]. Therefore, elucidation of the molecular mech-
anisms and associated factors involved in the establishment and
progression of NAFLD is crucially needed to identify new targets and
implement efficient therapies.
Currently, the association between the guteliver axis and gut micro-
biota is acquiring a major impact in the research on liver diseases as it
is indispensable for metabolic regulation, gut hormone release, and
immune responses [4]. A recent study of the metagenomic signature of
hepatic steatosis in a cohort of non-diabetic women with morbid
obesity has provided evidences on the association of hepatic steatosis
with low microbial gene richness and dysregulation of aromatic and
branched-chain amino acid metabolism [5]. The progression of NAFLD
to more severe stages also correlates with alterations in the intestinal
microbiota by affecting digestion, immune responses, and production
of gut hormones [6]. Moreover, Loomba and co-workers [7] in a cohort
of biopsy-proven patients with NAFLD with several degrees of fibrosis
have described a panel of gut microbiome biomarkers that can be used
as a non-invasive test to accurately diagnose advanced fibrosis in
patients with NASH. In addition, interventional studies with probiotics
such as VSL#3 and Lactobacillus casei Shirota and prebiotics such as
fermentable dietary fructo-oligosaccharides suggest that their
administration may improve NAFLD [8e10].
In the context of metabolic homeostasis, it is worth mentioning that the
intestine has a complex network of specialized cells known as
enteroendocrine cells (EECs) that secrete hormones to maintain energy
balance by regulating food intake, digestion, absorption, satiation,
storage, and disposal of digested nutrients [11]. Recent interest has
emerged on the interaction of EECs with the immune system and, in
this regard, plasma glucagon-like peptide (GLP)-1 levels rapidly in-
crease on lipopolysaccharide (LPS) administration in mice via a toll-like
receptor 4 (TLR4)-dependent mechanism [12,13]. Therefore, GLP-1
could be released to exert an anti-inflammatory effect in response to
a pro-inflammatory situation such as an increase in endotoxin or cy-
tokines [14].
Insulin resistance plays an important role in the development of NAFLD
[15]. Protein tyrosine phosphatase 1 B (PTP1B) is a phosphatase
ubiquitously expressed that acts as a negative regulator of insulin
action since it dephosphorylates tyrosine residues, primarily insulin
receptor (IR) and insulin receptor substrate 1 (IRS1), in critical nodes of
the insulin signaling cascade [16e18]. Global PTP1B-deficient mice
are resistant to diet-induced obesity [19] and do not show metabolic
alterations during aging such as fat mass accretion, hepatic steatosis,2 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. Tand hyperinsulinemia [20]. Of relevance, PTP1B is also an immune
modulator as it controls cytokine-mediated signaling by dephosphor-
ylating JAK2 in the JAK-STAT pathway and the non-receptor tyrosine
protein kinase 2 (TYK2), among others [21e23]. In this regard, a
previous study in our laboratory has evidenced an exacerbated
response of PTP1B-deficient versus wild-type (WT) macrophages to
pro-inflammatory stimuli with increased expression of M1 polarization
markers [24]. Furthermore, when challenged with a methionine and
choline-deficient (MCD) diet, PTP1B knockout (KO) mice developed
hepatic inflammation and NASH more rapidly than their WT counter-
parts. By contrast, when mice with established MCD-induced NASH
were switched to a chow diet, those lacking PTP1B manifested an
accelerated recovery due, at least in part, to hepatic oval cells prolif-
eration [25]. Taking all these data into account, we hypothesized that in
the context of the inflammatory environment associated with NASH,
PTP1B could modulate specific cellular mechanisms in the gut. Based
on that, in this work we have explored gut inflammation during NASH
and, particularly, the role of PTP1B in the gut barrier function asso-
ciated with this pro-inflammatory context. To achieve this goal, and
considering that PTP1B-deficient mice are protected against obesity-
induced NAFLD, an MCD dietary challenge was used as a preclinical
model of non-obese NASH [26]. Although the MCD diet has been
criticized because it causes body weight loss [27], it rapidly induces a
NASH signature correlative to that found in humans and, importantly, it
induces inflammation in the gut [28]. Our results have provided
experimental evidences of a role of PTP1B in the gut during NASH,
particularly with respect to gut microbiota, inflammation, and gut
barrier integrity.
2. MATERIALS AND METHODS
2.1. Animals
In this study we used WT mice (C57BL/6 J) or Ptpn1 heterozygous
mice of both sexes, maintained on a mixed genetic background
(C57BL/6 J  129 sv), that were intercrossed to yield the three ge-
notypes of mice (WT, heterozygous, and KO), as described previously
[20]. The mice were housed at the animal facilities of the Alberto Sols
Biomedical Research Institute (CSIC-UAM, Madrid). To induce experi-
mental NASH, 12- to 16-week-old PTP1B WT or Ptpn1 KO (PTP1B KO)
male mice were fed a MCD diet (TD-90262 Harlan-Tecklad, Indian-
apolis, IN, USA) up to 4 weeks. The control animals were fed a chow
diet during this period. Body weight was monitored weekly. Mice were
maintained in 12-hour light/dark, temperature-controlled (22 C), and
humidity-controlled rooms. All animal experimentation was conductedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in accordance with Spanish and European legislation and UK animals
(Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/
3039), and approved by the CSIC and Comunidad de Madrid Animal
Care and Use Committees and the University of Cambridge Animal
Welfare and Ethical Review Body.
2.2. Microbiome analysis
Fecal content was freshly collected individually, weighed, and frozen
at80 C until use. Genomic DNA was extracted using the FastDNA
SPIN Kit for Soil (MP Biomedicals, CA, USA) following the manufacturer’s
instructions. The homogenization step was conducted in a FastPrep
Instrument (MP Biomedicals, USA) for 10 s at a speed setting of 5.5. DNA
quantity and quality were measured using the NanoVue plus system (GE
Healthcare Life Science, UK). All samples were diluted to a 100 ng/mL
final concentration. Polymerase chain reaction (PCR) amplification of
V3eV4 hypervariable regions of 16 S rRNA genes was performed using
the following primers [29]: 16SV3V4-Fw: ACACTGACGACATGGTTCTA-
CACCTACGGGNGGCWGCAG and 16SV3V4-Rv: TACGGTAGCAGA-
GACTTGGTCTGACTACHVGGGTATCTAATCC. Sequencing was performed
in the Genomic Unit at Parque Cientifico de Madrid (Spain) using the
Illumina-Myseq system (Illumina, San Diego, CA) following the manu-
facturer’s guidelines. An average of 160,000 readings per sample was
obtained. Paired reads were joined using the PandaSeq Assembler. Only
sequences ranging from 300 to 460 bp were considered. Operational
taxonomic units (OTUs) were determined using the GreenGenes 13_5
reference sequences database. The Miseq sequences derived from the
16 S profiling were deposited in the European Nucleotide Archive and
are available under the following accession number: PRJEB13752.
Community diversity (a-diversity) was calculated using Quantitative In-
sights into Microbial Ecology (QIIME) with the Shannon index [30]. QIIME
was used to determine b-diversity by calculating the weighted and
unweighted UniFrac distances [31]. EMPEROR was employed to visu-
alize a UniFrac PCoA biplot. 16 S rDNA data were analyzed by the
software Phylogenetic Investigation of Communities by Reconstruction of
Unobserved States (PICRUSt) to predict metagenomics functional con-
tent by using OTUs picked against Greengenes 13_5 and Kyoto Ency-
clopedia of Genes and Genomes (KEGG) databases [32].
2.3. FITC-dextran assay
A 60 mg per 100 g of body weight dose of fluorescein isothiocyanate
(FITC)-Dextran (FITC-Dextran 4 kDa, Sigma Aldrich, USA) dissolved in
sterile phosphate-buffered saline (PBS) was administered by oral
gavage to PTP1B WT or PTP1B KO mice fed a MCD or chow diet. Blood
samples were collected by submandibular bleeding after 4 h in special
tubes for small volumes (SST Tubes BD Microtainer). Serum was
obtained after centrifugation at 3000  g for 10 min at 4 C, and
fluorescence was measured at 485 nm (excitation) and 535 nm
(emission) with the Fluorometer Biotek Synergy HT and analyzed
with GEN 51.07 software. The FITC-Dextran concentrations were
determined from a standard curve with serial dilutions of FITC-Dextran.
2.4. Measurement of circulating endotoxemia
Blood was collected from PTP1B WT and PTP1B KO mice fed a chow or
MCD diet for 4 weeks in glass tubes (TU04-127-250, Labbox, Bar-
celona, Spain). Serum samples were obtained after centrifugation at
3000 g for 10 min and stored in glass vials (SV02-A20-100, Labbox,
Barcelona, Spain) at 80 C. Endotoxemia was determined by
enzyme-linked immunosorbent assay (ELISA) with the Mouse Endo-
toxin (ET) ELISA Kit (QAYEE-BIO, China) following the manufacturer’s
instructions.MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
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The colon was removed, and its length and weight were measured.
Once the luminal content was removed with PBS, 5-mm pieces were
cut and fixed with Methacarn (60% methanol, 30% chloroform, and
10% acetic acid) for 24 h at 4 C. After fixation, pieces were washed
with PBS and paraffin-embedded as follows: dehydration: 3  1 h in
96% ethanol, 3  1 h in 100% ethanol, 3  1 h in isoparaffin; par-
affinization: 3  2 h in paraffin in a 60 C oven. Next, 5-mm-thick
sections were obtained using a standard microtome (Microm) and
mounted on silanized glass slides for staining.
2.6. Evaluation of colon mucosal integrity and crypt length
Once the samples were dewaxed and rehydrated, they were stained
using the hematoxylin and eosin (H&E) technique as follows. Sections
were immersed in filtered Harris Hematoxylin for 10 s, washed with tap
water, immersed in eosin for 30 s, washed with tap water, and
dehydrated in ascending alcohol solutions. Colon sections stained with
H&E were evaluated by a single blinded pathologist looking for in-
flammatory infiltrates, epithelial changes such as hyperplasia, and
altered crypt architecture. Colon images were taken with the slide
scanner Axio Scan. Z1 (Zeiss, Germany). Crypt lengths (mm) were
quantified in periodic acid-Schiff (PAS)-stained sections using the Fiji
version of Image J software (http://fiji.sc/Fiji). Measurements were
taken from at least 27 full-length crypts obtained from five different
longitudinal sections (per mouse).
2.7. Analysis of colonic neutral and acid mucins
Colonic mucins were determined following the PAS histochemical
technique [33] and alcian blue (AB) stains. Briefly, 5-mm sections were
stained with AB for 15 min and washed with distilled water. Then,
samples were treated with periodic acid (1%) for 5 min, washed with
distilled water, treated with the Schiff reagent for 5 min, and washed
again. Finally, nuclei were counterstained using Harris Hematoxylin for
2 min. The neutral mucins were stained in magenta, whereas the acid
mucins were stained in blue. The Fiji version of ImageJ software was
used to obtain neutral and acid mucin scores. Results, expressed in
arbitrary units (A.U.), correspond to the optical intensity  surface of
magenta and blue staining after spectral separation of both colors.
Only intact crypts were quantified.
2.8. Measurement of colon edema
The colon was sectioned in 1-cm pieces after its extraction. Sections
were homogenously distributed over a filter and placed into the
moisture analyzer MB120 (Ohaus, Switzerland). Moisture was deter-
mined from the weight loss of the sample dried by heating. The
temperature profile selected was a standard drying at 140 C. The
drying was considered finished when no changes at the level of mil-
ligrams were produced for at least 180 s.
2.9. ZO-1 immunofluorescence
Five-micron colonic paraffin sections were dewaxed and rehydrated.
Antigen retrieval was performed with 10 mM sodium citrate and 0.05%
Tween-20 (pH 7.4) for 10 min at 100 C. H2O2 (3%): methanol (1:1)
was used to block endogenous peroxidase for 30 min. Blocking was
performed with 5% bovine serum albumin (BSA) and 4% goat serum
for 1 h at room temperature. Samples were incubated with 1:50 anti-
zonula occludens-1 (ZO-1) antibody (ZO-1-1A12, Invitrogen) overnight
at 4 C. Incubation with secondary antibody Rhodamine Red-X
(Jackson ImmunoResearch) and 4,6-diamino-2-phenylindole (DAPI;
Sigma) was performed for 1 h at room temperature. Images wereaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
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Germany).
2.10. RNA isolation and quantitative real-time PCR analysis
The colon was immediately frozen in liquid nitrogen after its collection.
Colon homogenization was performed using the Tissue Lyser LT
(Qiagen, Hilden, Germany) for 4 min, 30 s in TRIzol Reagent (Invi-
trogen, USA) followed by a chloroform and isopropanol extraction. We
used the Turbo DNA-free kit (Invitrogen by ThermoFisher Scientific,
USA) for DNA digestion and the iScript cDNA Synthesis Kit (BioRad,
USA) to conduct the cDNA synthesis following the manufacturer’s in-
structions. SYBER Green-based quantitative PCR was performed with
Kapa SYBR FAST (Kapa Biosystems, Roche, Switzerland). Quantifi-
cation was done through delta Ct analysis.
2.11. GLP-1 measurement in plasma
Overnight fasted mice were administered a dose of 6 g/kg glucose by
oral gavage. After 10 min, blood samples were collected in cold eth-
ylenediamine tetraacetic acid (EDTA) tubes (BD Vacutainer spray-
coated K2EDTA Tubes, BD, USA) containing dipeptidyl peptidase-IV
(DPP-IV) inhibitor (DPP4, EMD Millipore, USA) at a final concentration
of 25 mM. Blood samples were centrifuged at 3000  g for 10 min at
4 C. After collection of plasma samples, DPP-IV inhibitor was added
up to a final concentration of 50 mM, and samples were then imme-
diately frozen and stored at 80 C. GLP-1 was determined using a
total GLP-1 assay kit (MesoScale Discovery, USA).
2.12. Acute pro-inflammatory systemic model in mice
C57BL/6 J male mice were treated with a single intraperitoneal in-
jection of LPS (2 mg/kg body weight). For GLP-1 measurement, plasma
samples were collected 16 h after the LPS challenge following 4 h of
fasting and administration of 6 g/kg glucose by oral gavage as pre-
viously described.
2.13. Plasma bile acids profiling
After protein precipitation with 3 volumes of cold (20 C) acetonitrile,
samples were centrifuged. The separated supernatant solvent was
evaporated, and the residue was resuspended in methanol:water
(same volume as plasma). The plasma bile acids content was deter-
mined by ultra-high performance liquid chromatography (UHPLC) using
a 1290 Infinity II LC System connected to a 6460 Triple Quadrupole MS
as the instrument detector, both from Agilent Technologies (Santa
Clara, CA, USA). A Zorbax Eclipse Plus C8 2.1  150-mm 1.8-mm
column (Agilent Technologies, Spain) and an optimized gradient with
acetonitrile, methanol, and ammonium acetate (pH 4) were used for
bile acid separation. The analysis was performed at the Center for
Metabolomics and Bioanalysis (CEMBIO), Universidad CEU-San Pablo,
Madrid, Spain, based on previously described methodology [34] with
slight modifications. Commercial standards from Sigma (St. Louis, MO,
USA) were used for all the bile acid measurements. D4-deoxycholic
acid was used as the internal standard (IS). Calibration curves were
prepared with seven concentrations of each standard.
2.14. Conditioned media production in macrophages
Raw 246.7 murine macrophages cell line was used to obtain a pro-
inflammatory macrophage-conditioned medium (mCM) for perform-
ing in vitro experiments. Macrophages were cultured in T75 flasks (BD
Falcon, USA) in Roswell Park Memorial Institute (RPMI) 1640 me-
dium supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics (1% P/S; 100 U/mL penicillin, 100 mg/mL
streptomycin) at 37 C in a humidified atmosphere with 5% CO2.4 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. TMedium was collected after the treatment of confluent macrophages
with 100 ng/mL LPS (InvivoGen, California, USA) with or without
20 mM of PTP1B inhibitor (Ref. 539,741, SigmaeAldrich) in Dulbecco
modified Eagle medium (DMEM) supplemented with 2% FBS and 1%
P/S for 16 h [referred to as mCM-lipopolysaccharide (mCM-LPS)]. As a
control, mCM was collected from unstimulated macrophages main-
tained for the same time period in DMEM-2% FBS-1% P/S (referred to
as mCM-C).
Peritoneal macrophages were plated at 10-12 106 cells per dish and
maintained in RPMI medium supplemented with 10% FBS and 1% P/S
for 2 h. Then, the medium was changed to DMEM supplemented with
2% FBS and 1% P/S for 24 h. To obtain the CM, macrophages were
treated or not with 150 ng/mL LPS for 18 h in DMEM-2% FBS-1% P/S
(referred as pCM-LPS or pCM-C, respectively).
2.15. Culture of STC-1 enteroencocrine cells
Confluent STC-1 (intestinal secretin tumor-1) cells were maintained in
DMEM supplemented with 10% FBS and 1% P/S. For experiments,
STC-1 cells were treated with mCM-LPS or mCM-C for several time-
periods to analyze pro-inflammatory signaling cascades or for 16 h
prior to stimulation with 1 nM insulin (SigmaeAldrich, Missouri, USA)
for 10 min to analyze insulin signaling. To inhibit PTP1B enzymatic
activity, STC-1 cells were pretreated with the PTP1B inhibitor (20 mM)
for 2 h prior to the treatment of the cells with either mCM. We also
supplemented the mCM with the same concentration of the inhibitor
thorough the experiment. Then, the cells were washed twice with PBS
and collected for further analysis.
2.16. Analysis of protein expression by western blot
STC-1 cells were homogenized in lysis buffer containing 10 mM Trise
HCl, 1 mM MgCl2, 1 mM Ethylene glycol-bis(2-aminoethylether)-
N,N,N0,N0-tetraacetic acid (EGTA), 10% glycerol, 0.5% 3-[(3-Chol-
amidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS),
1 mM b-mercaptoethanol, 0.1 mM phenymethylsulfonyl fluoride
(PMSF), and 5 mg/mL of a protease and phosphatase inhibitor cocktail
(SigmaeAldrich, USA), pH 7.5. The extracts were centrifuged for
20 min at 13,000  g at 4 C, and supernatants were stored
at 20 C. Protein levels were determined using the Bradford dye
method (Bio-Rad, USA). Protein extracts were boiled at 95 C for 5 min
in loading buffer [250 mM TriseHCl, pH 6.8, 2% sodium dodecyl
sulfate (SDS), 10% glycerol, and 2% b-mercaptoethanol] and sub-
jected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
were then transferred onto nylon membranes (Immobilon P, Millipore,
USA). Blots were incubated for 2 h at room temperature or overnight at
4 C with primary antibodies against phospho-AKT Ser308, phospho-
AKT Ser473, phospho-IR, phospho-JNK and phospho-p65 NFkB (nu-
clear factor kappa-light-chain-enhancer of activated B cells) (Cell
Signaling Technology, USA), AKT, (IkBa) inhibitor of kappa B, insulin
receptor (IR), Vinculin, and JNK (Santa Cruz Biotechnology, USA).
Finally, the blots were developed with Clarity ECL Western Blot (Bio-
Rad). Values of scanning densitometry were determined using the
Quantity One software (Bio-Rad, UK).
2.17. Lentiviral silencing of Ptpn1 in Caco-2 cells
A stable cell line of Caco2 silenced for Ptpn1 gene, that encodes PTP1B
protein, was generated by transduction with a battery of lentiviral
particles TRCN0000218522, TRCN0000226109, TRCN0000226108,
TRCN0000226107, and TRCN0000226106 (Mission shRNA Trans-
duction Particles, Sigma Aldrich, USA) following the manufacturer’s
protocol. Lentiviral particles with Scramble shRNA were used as a
control. Transduced cells were selected with puromycin (2.5 mg/mL)his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for 2 weeks. Transduction was confirmed by measuring Ptpn1
expression by RT-qPCR. Stable cell-lines were obtained and referred
as Caco-2 Scramble (Caco-2 shScrb) and Caco-2 shPtpn1.
2.18. Determination of TransEpithelial Electrical Resistance (TEER)
For the analysis of TEER, Caco-2 cells (epithelial cells from human
colon adenocarcinoma) were grown in (EMEM) Minimum Essential
Medium - Eagle with Earle’s BSS (Lonza, Switzerland) supplemented
with 20% FBS and 1% P/S on porous filter membranes (0.4 mm-
diameter pore) (Transwell Permeable Support 0.4 mM Polyester
Membrane Ref. 3460, Costar, Strasbourg, France). TEER was
measured with a Millicell-ERS system (Millipore, USA) every 3 days
until cells formed a monolayer. A monolayer was considered to be
formed when three consecutive stable TEER measurements were
obtained. Caco-2 cells were treated with mCM-C or mCM-LPS, and
TEER was measured at the indicated time points.
2.19. Two-dimensional (2D) organoid culture and analysis of GLP-
1 secretion
Transgenic mice (GLU-Epac2camps) bearing glucagon promoter-
driven YFP expression that marks functional enteroendocrine (EEC) L
cells were used. Colonic intestinal organoid lines were established
using the procedure described previously [35] and underwent a dif-
ferentiation protocol, which involved withdrawal of Wnt3A 5e7 days
before plating in a 2D culture. For plating 2D organoid cultures,
differentiated organoids were collected in ice cold advanced
DMEM:F12 (ADF) medium (Life Technologies, USA) and centrifuged at
200 g for 5 min. The pellet was broken up enzymatically with TrypLE
(Gibco, Thermofisher, USA) for 2 min at 37 C and neutralized with ADF
supplemented with 10% FBS and 10 mM ROCK inhibitor y27632
(Tocris, USA). Resulting single cells and clusters were centrifuged at
300 g for 5 min, resuspended in organoid medium, and seeded onto
2% Matrigel-coated 48-well plates for GLP-1 secretion measurement
[36]. After overnight incubation (37 C, 5% CO2), 2D cultures were
washed three times in warm standard saline solution 138 buffer
[consisting of (in mM) NaCl (138), KCl (4.5), HEPES (10), NaHCO3 (4.2),
NaH2PO4 (1.2), D-glucose (1), CaCl2 (2.6), MgCl2 (1.2); pH 7.4 with
NaOH] and 0.1% fatty acid-free BSA. Cells were incubated with pCM-C
or pCM-LPS at 37 C for 6 h. Supernatants were removed from the
organoids and centrifuged at 2000 g for 5 min at 4 C, transferred to
a fresh tube, and snap frozen on dry ice. Meanwhile, cells were lysed
in 150 mL of lysis buffer on ice, and frozen overnight before lysates
were scraped, collected, and centrifuged at 10,000  g for 10 min at
4 C. Samples were stored at 80 C until measurement by the Core
Biochemistry Assay Lab facility (Cambridge, UK). GLP-1 levels were
measured using the total GLP-1 ELISA kit (MesoScale Diagnostics,
USA) following the manufacturer’s instructions [36].
2.20. Colonic epithelial cultures and analysis of GLP-1 secretion
Colonic crypts were isolated and cultured from 3- to 6-month-old
C57BL/6 J mice of either sex as previously described [37]. Mice were
euthanized, and the colon was excised. Luminal contents were flushed
with cold PBS, and the outer muscle layer was removed. Tissues were
minced and digested with collagenase type XI (0.35 mg/mL). Crypt-
containing fractions were centrifuged at 100  g for 3 min and
resuspended with DMEM supplemented with 10% FBS, 1% P/S, and
2 mM L-glutamine (Gibco, Life Technologies) before filtering through a
70-mm cell strainer. Colonic crypts were plated onto Matrigel (BD
Bioscience) coated 48-well plates and placed overnight in a 5% CO2
incubator at 37 C. For analysis of GLP-1 secretion, primary colonicMOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comepithelial cultures were seeded into 48-well plates as already
described. After 1 day in culture, the culture medium was exchanged
for fresh warmed medium with or without the PTP1B inhibitor (20 mM)
or vehicle (DMSO) as a control. After incubation at 37 C for 2 h, the
culture medium was replaced by pCM-C or pCM-LPS for a further 6 h.
An additional control group of culture medium was included (RPMI-2%
FBS not exposed to macrophage cultures). The PTP1B inhibitor was
kept during all the treatments. Supernatant and lysate samples were
collected and processed for GLP-1 as previously indicated.
2.21. Statistical analysis
Statistical analysis was performed using GraphPad Prism v5. Sample
outliers were found using the Grubbs test. The ShapiroeWilk test was
run to determine whether the samples showed a parametric or non-
parametric distribution. Unpaired two-tailed Student’s t-tests were
used to do pairwise comparisons in parametric distributions, and the
ManneWhitney U test was used for non-parametric distributions. Two-
way analysis of variance (ANOVA) with post-hoc Tukey test was
employed to compare two different categorical independent variables
(i.e., diet and genotype). When another statistical analysis different
from the one described was used, it is indicated in the description of
the corresponding result. The data are presented as the
mean  standard error of the mean (SEM). Differences were
considered statistically significant when p < 0.05.
3. RESULTS
3.1. Characterization of gut microbiota in PTP1B WT and PTP1B KO
mice during NASH
PTP1B WT and PTP1B KO mice were fed a chow or MCD diet for 4
weeks, and 16s rRNA microbiome analysis of feces was performed at
the end of the treatment. a-diversity, determined by the Shannon index
[38], showed a trend to a decrease in mice from both genotypes fed a
MCD diet; this effect was statistically significant only for PTP1B KO
mice (Figure 1A). The analysis of b-diversity showed a marked dif-
ference between fecal microbiota of mice fed chow or MCD diets with a
clear separation of both clusters of samples along the experimental
protocol (Figure 1B). Furthermore, a separation in PTP1B WT and
PTP1B KO clusters was appreciated particularly during NASH. Fecal
profiling analyzed by unweighted UniFrac algorithm evidenced signif-
icant differences in microbiota composition between groups at
different taxonomic levels (Table 1). As expected, the phyla Firmicutes
and Bacteroidetes represent more than 80% of all bacterial species in
mice fed a chow diet, and no differences between genotypes were
found in the Firmicutes/Bacteroidetes (F/B) ratio (Figure 1C). However,
in PTP1B WT mice under a MCD diet, the abundance of Firmicutes
increased, whereas a marked decrease was observed in Bacter-
oidetes, leading to a higher F/B ratio. Of note, no changes in F/B ratio
were found in MCD diet-fed PTP1B KO mice compared with their
genotype counterparts fed a chow diet. Phylum TM7 abundance also
exhibited a decrease in animals fed a MCD diet; these changes were
statistically significant only for PTP1B KO mice (Table 1). At the family
level, we found that S24-7, Lactobacillaceae, and Mogibacteriaceae
families decreased similarly in both genotypes during NASH, whereas
Lachnospiraceae and Dehalobacteriaceae decreased only in PTP1B WT
mice. Moreover, families Turicibacteriaceae and Verrucomicrobiaceae
appear to be decreased in PTP1B KO mice after 4 weeks on the MCD
diet. Conversely, families Porphyromonadaceae, Rikenellaceae, and
Erysipelotrichaceae were increased in both genotypes during NASH,
whereas Turicibacteriaceae increased only in MCD diet-fed PTP1B WTaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 1: Gut microbiota composition and functional changes. A) Alpha-diversity analysis for PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks. Shannon
index is expressed as mean  SEM. ###p < 0.001 PTP1B KO chow vs PTP1B KO MCD. B) Phylogenetic b-diversity of fecal microbiota. Graph represents principal coordinate
analysis (PCoA) plot based on 16 S rRNA gene sequencing of stool samples from PTP1B WT (blue symbols) and PTP1B KO (red symbols) mice fed a chow or MCD diet for 4 weeks.
Differences between genotypes in this case are indicated with different clouds. Pink cloud corresponds to animals fed chow diet and green cloud surrounds animals fed a MCD diet.
C) Ratio Firmicutes/Bacteroidetes (F/B) is expressed as mean  SEM. *p < 0.05 PTP1B WT chow vs PTP1B WT MCD. D-E) Predicted functional changes in gut microbiota analyzed
by PICRUSt tool. Bar graphs show significant differences in KEGG pathways. MCD_1 M refers to animals fed a MCD diet for 4 weeks; Chow_ refers to animals fed a chow diet.
Significant differences are shown as p-value at the right panel. n ¼ 5e7 mice per experimental group.
Original Articlemice. Finally, at the genus level, Adlercreutzia, Lactobacillus, Rose-
buria, and Desulfovibrio showed a decrease with NASH in both ge-
notypes, whereas an increase in Parabacteroides and Allobaculum
relative levels were observed. In this regard, only MCD diet-fed PTP1B
KO mice exhibited an increase in Prevotella and a decrease in Turi-
cibacter, whereas PTP1B WT mice showed an increase in Turicibacter
genera during NASH (Table 1).6 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. TBiochemical function of the microbial community was determined
using PICRUSt software, which allows prediction of the functional
characteristics of the gut microbiota under the different experimental
conditions. PICRUSt analysis showed that the genes related to meta-
bolism of cofactors/vitamins and energy balance were significantly
underrepresented in PTP1B WT mice fed a MCD diet compared with
their corresponding controls fed a chow diet (Figure 1D), and thesehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 e Changes in gut microbiota composition at different taxonomic levels during NASH in PTP1B WT and PTP1B KO mice.
Changes in microbiota 
Comparison1 Phylum Family Genus 
Chow vs MCD 
dieta 
Actinobacteria Coriobacteriaceae Adlercreutzia↓*** 
Bacteroidetes↓*w Porphymonadaceae↑* Parabacteroides↑* 
   
 Prevotellaceae Prevotella↑**k 
 S24-7↓***  
 Rikenellaceae↑*  
Firmicutes↑*w Lactobacillaceae↓* Lactobacillus↓** 
   
 Turicibacteraceae↑***w Turicibacter↑***w 
 Dehalobacteriaceae↓**w  
 Lachnospiraceae↓*w Roseburia↓* 
 Mogibacteriaceae↓*  
 Erysipelotrichaceae↑* Allobaculum↑* 
Ratio F/B↑*w   
Proteobacteria Desulfovibrionaceae Desulfovibrio↓* 
 TM7↓*k   
Wild-type vs 
PTP1B-/-b 
Bacteroidetes Prevotellaceae Prevotella↑**m 
 Turicibacteraceae↓***m Turicibacter↓***m 
Verrucomicrobia Verrucomicrobiaceae↓*m  
1Comparison between the different conditions. Two-way ANOVA with a Tukey post-hoc test was performed for statistical analysis. aChanges in gut microbiota due to the administered
diet. [ expresses higher abundance and Y indicates lower abundance after 4 weeks of MCD diet relative to chow diet. bChanges in gut microbiota due to the genotype. [ indicates
higher and Y indicates lower abundance in PTP1B KO mice vs PTP1B WT mice. Taxa with differences due to diet and genotype are shown highlighted in purple. w refers to significant
differences found only for PTP1B WT animals; k refers to significant differences found only for PTP1B KO animals. m refers to significant differences found only in MCD-fed animals.
*p<0.05; **p<0,01; ***p<0.001. n¼5-7 animals per condition.changes were not found in PTP1B KO mice. Moreover when we
compared both genotypes in MCD diet-fed animals, we found that
microbiota from PTP1B WT mice were significantly enriched in genes
for secondary bile acid biosynthesis compared with PTP1B KO mice,
whereas microbiota from PTP1B KO mice were enriched in genes
related to propanoate metabolism compared PTP1B WT mice during
NASH (Figure 1E).
3.2. Effect of PTP1B deficiency on serum bile acids during NASH
Bile acids are mediators in the cross-talk between the liver and gut and
can modulate gut microbiota and also be modulated by the host gut
microbiota [39]. We quantified bile acids in serum to verify if their
levels were altered in the context of PTP1B deficiency and/or MCD diet-
induced NASH. Cholic (CA), chenodeoxycholic (CDCA), and ursodeox-
ycholic (UDCA) primary bile acids in mice were significantly augmented
in serum of PTP1B WT mice receiving the MCD diet, but this increase
did not reach significance in PTP1B KO mice as depicted in Figure 2Ae
C. Moreover, taurocholic (TCA) and taurochenodeoxycholic (TCDCA)
acids, also primary bile acids resulting from the conjugation with
taurine of CA and CDCA, respectively, exhibited higher levels in serum
in the NASH condition, but no differences were found between ge-
notypes (Figure 2DeE). We also found changes in CDCA-derived tauro
a-muricholic acid (TaMCA), a primary bile acid in mice [40]. As shown
in Figure 2F, its serum levels were more elevated in PTP1B KO mice. In
addition, the secondary bile acid taurodeoxycholic (TDCA) increased in
MCD diet-induced NASH exclusively in PTP1B WT mice (Figure 2G).MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
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farnesoid X receptor (FXR), in the gut showed higher levels in PTP1B
KO mice under NASH (Figure 2H).
3.3. Differential alterations in gut barrier permeability in PTP1B WT
and PTP1B KO mice during NASH
We measured endotoxin levels in serum samples as an indicator of
microbial product translocation, and higher circulating endotoxin
levels were found in mice from both genotypes fed a MCD diet
during 4 weeks compared with animals receiving a chow diet
(Figure 3A). However, endotoxin levels were lower in MCD diet fed-
PTP1B KO mice. Intestinal permeability was also analyzed by an
in vivo FITC-dextran assay. Figure 3B shows that, in agreement with
endotoxin levels, PTP1B WT mice showed a more pronounced in-
crease in serum FITC-dextran levels after NASH induction, reflecting
increased intestinal permeability compared with PTP1B KO mice.
Better preservation of the gut barrier under NASH conditions in
PTP1B KO mice was also confirmed by ZO-1 immunostaining
(Figure 3C).
We used human Caco-2 colon cells infected with lentiviral particles
encoding scrambled shRNA (shScrb) or Ptpn1 shRNA (shPtpn1) to
measure TEER, a common method for in vitro analysis of the barrier
properties in epithelial intestinal cells [41,42]. A comparison between
the TEER values of Caco-2 shScrb and Caco-2 shPtpn1 cell lines
treated with mCM collected from Raw 264.7 macrophages without
(mCM-C) or with (mCM-LPS) LPS stimulation as described in theaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 2: Bile acid levels in serum samples from PTP1B WT and PTP1B KO mice fed chow or MCD diet. A-G) Mean  SEM of bile acids concentrations in serum samples are
expressed as part per billion (ppb). n ¼ 10e15 mice per experimental group. H) Nr1h4 mRNA levels in the gut (encoding FXR protein). White dots represent mice fed a chow diet
and black dots represent mice fed a MCD diet. n ¼ 10e15 mice per experimental group. *p< 0.05; **p < 0.01; PTP1B WT chow vs PTP1B WT MCD; #p < 0.05; ##p < 0.01
PTP1B KO chow vs PTP1B KO MCD; þp < 0.05; þþp < 0.01 PTP1B WT MCD vs PTP1B KO MCD.
Original ArticleMaterials and Methods is shown in Figure 3D, and the raw data of
TEER values are included in Supplementary Table 1. After 24 and 48 h
of treatment of Caco-2 shScrb or shPtpn1 cell lines with mCM-LPS,
TEER measurements decreased significantly to approximately half
the levels detected in cells treated with mCM-C regardless of PTP1B
expression. These results indicate that PTP1B deficiency does not
directly impact on the barrier properties in the monolayer system of
Caco-2 cells.
3.4. Colonic changes in PTP1B WT and PTP1B KO mice during
NASH
Interestingly, under basal conditions (chow diet), colonic crypts were
51.6%  22.46% deeper in mice with deletion of the Ptpn1 gene
compared with PTP1B WT control mice (p < 0.05). Colitis is usually
associated with the presence of edema due to alterations in lymphatic
vessel function triggered by the inflammatory mediators [43e45].
Because MCD diet-induced NASH generates a pro-inflammatory
environment [46], we tested the presence of edema through the
analysis of colon moisture content. Figure 4A shows an increase in
colon water content of 3% and 4% in MCD diet-fed PTP1B WT and
PTP1B KO animals, respectively, which reached significance only in
PTP1B KO mice. However, when we determined the colon weight/
length-to-body weight ratio, a parameter used to determine colon
edema [47,48], no differences were found between the four groups of
animals (Supplementary Fig. 1A), an effect probably due to the
decrease of body mass associated with MCD administration. There-
fore, it seems that this parameter does not determine colon edema in a
pathological model such as MCD diet-induced NASH. Furthermore, we8 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. Tanalyzed the bowel content searching for diarrhea, a symptom of
advanced colitis. Surprisingly, MCD diet-fed animals exhibited lower
number of fecal pellets and lower water content in colon feces
(Supplementary Figs. 1BeC).
The histopathological analysis of colon samples did not show sub-
stantial changes in tissue epithelium such as hyperplasia or altered
mucosa architecture. However, colonic mucosa from PTP1B KO mice
contained unspecific granulomas not only after the challenge with MCD
diet, but also before the induction of NASH (Figure 4BeC). Further-
more, PAS and AB staining was performed in colonic sections to
evaluate colon mucosal integrity. Figure 4D shows decreased mucin
levels in both genotypes of mice during NASH. Results for Muc2 (the
gene encoding for Mucin-2) mRNA levels in colon corroborated this
decrease (Figure 4E).
Beyond epithelial and endocrine cells [49], the intestine comprises a
complex network of immune cells. Among them, a specialized gut
immune cell population known as intraepithelial lymphocytes (IELs)
modulates innate immunity and controls gut barrier function, epithelial
turnover, and the host response to enteric pathogens [13]. Based on
that, we analyzed the expression of T-cell surface glycoprotein CD3g
(Cd3g) as the IEL marker in colon samples. As depicted in Figure 5A,
PTP1B KO mice exhibited a greater than two-fold increase in Cd3g
mRNA levels compared with PTP1B WT mice on a chow diet. Similar
results were obtained when we evaluated the natural killer and cyto-
toxic T lymphocyte marker granzyme B (Gzmb) (Figure 5B). Likewise,
the analysis of interferon gamma (Ifng) expression levels, a natural
killer and CD4 Th1/CD8 cytotoxic T lymphocyte marker, showed an
increase in PTP1B KO mice fed a MCD diet compared with PTP1B WThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Alterations in the gut barrier permeability in PTP1B WT and PTP1B KO mice during NASH. A) LPS levels in serum after 4 weeks of feeding mice a chow or MCD
diet. n ¼ 6e9 mice per group. B) FITC-dextran assay in PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks. Data are expressed as percentage of FITC-dextran
levels absorbed in serum samples. n ¼ 9e16 animals per experimental group. ***p < 0.001 PTP1B WT chow vs PTP1B WT MCD; ###p < 0.001 PTP1B KO chow vs PTP1B KO
MCD; þþp < 0.01 PTP1B WT MCD diet vs PTP1B KO MCD diet. C) Representative images of ZO-1 immunostaining in colon samples of PTP1B WT and PTP KO mice. Scale bar
50 mm. D) Effect of the pro-inflammatory environment on TEER values in Caco-2 shScrb and Caco-2 shPtpn1 monolayers. TEER values from Caco-2 shScrb or shPtpn1 cultured in
Transwell plates treated with mCM-C or mCM-LPS are represented as percentage of baseline. Data are expressed as mean  SEM of three independent experiments performed in
triplicate. ***p < 0.001 Caco-2 shScb mCM-LPS vs mCM-C; ###p < 0.001 Caco-2 shPtpn1 mCM-LPS vs mCM-C.animals under the same conditions (Figure 5C). In light of these results,
the expression levels of the inducible nitric oxide synthase (Nos2) were
higher in PTP1B KO mice compared with PTP1B WT animals after
NASH induction (Figure 5D). Taken together, these results along with
the presence of edema (Figure 4A) and the mucosal inflammation
noted in PTP1B KO mice, particularly during NASH (Figure 4BeC), shed
light on an effect of PTP1B deficiency on constitutive colonic mucosalMOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.cominflammation further exacerbated during MCD diet-induced NASH.
Interestingly, Ptpn1 levels were decreased in colon samples from
PTP1B WT mice, reflecting an inverse relationship between this
phosphatase and inflammation (Figure 5E). Conversely, the evaluation
of mRNA levels of genes encoding pro-inflammatory cytokines
[interleukin-1 beta (IL-1b), tumor necrosis factor alpha (TNFa), and
transforming growth factor beta (TFG-b)] and fibroblast growth factor 7access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 4: Analysis of anatomical and histological parameters in colon samples from PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks. A) Colon
moisture content is expressed as percentage of water regarding total colon weight. n ¼ 7e8 mice per experimental group. B) Colonic epithelial granuloma areas expressed as
percentage of total epithelium area. n ¼ 4 mice per experimental group. C) Representative images of H&E colonic stained sections from PTP1B WT and PTP1B KO mice. Images
were taken from 5 mm colon paraffin-embedded sections stained with H&E with an Axio Scan. Z1 (Zeiss). Granuloma areas are marked with a white symbol. D) Mucin layer
analysis in colonic samples from mice under NASH conditions. Images show AB (left) (n ¼ 8e16 crypts per experimental group) and PAS (right) stained representative crypts from
colonic sections that stain acidic and neutral mucins, respectively (n ¼ 17e24 crypts per experimental group). E) Muc2 (mucin) mRNA levels are shown as fold change referred to
the control PTP1B WT fed a chow diet. Data are expressed as mean  SEM. n ¼ 5e8 mice per experimental group. *p < 0.05; **p < 0.01 PTP1B WT chow vs PTP1B WT MCD;
#p < 0.05; ###p < 0.001 PTP1B KO chow vs PTP1B KO MCD.
Original Article
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Figure 5: mRNA expression levels of pro-inflammatory markers in colon samples of PTP1B WT and PTP1B KO mice during NASH. A-E) Cd3g (T-cell surface glycoprotein
CD3 g), GzmB (granzyme B), Ifng (interferon gamma), Nos2 (inducible nitric oxide synthase), and Ptp1n (PTP1B) mRNA levels are shown as fold change referred to the control
PTP1B WT fed a chow diet. White dots correspond to mice fed a chow diet and black dots to mice fed a MCD diet during 4 weeks. Data are expressed as mean  SEM. n ¼ 5e10
mice per experimental group. ***p < 0.001 PTP1B WT chow vs PTP1B WT MCD; ##p < 0.01 PTP1B KO chow vs PTP1B KO MCD; þp < 0.05; þþ p< 0.01; þþþp < 0.001 PTP1B
WT MCD vs PTP1B KO MCD.(FGF7) in colon samples did not show significant differences among
the experimental groups (data not shown).
3.5. Impact of PTP1B deficiency on GLP-1 secretion, EECs pro-
inflammatory-mediated signaling, and expression of GLP-2 target
genes
It has been demonstrated that glucagon-like peptide-1 (GLP-1) binds
to GLP-1R in IELs and suppresses the pro-inflammatory cytokine
program, thereby protecting against gut inflammation [13]. To assess
the ability of a pro-inflammatory stimulus to induce GLP-1 secretion
in vivo, we injected C57BL/6 J mice with a single dose of LPS (2 mg/
kg), and plasma GLP-1 levels in response to an oral glucose challenge
were analyzed 16 h later. As shown in Figure 6A, a three-fold increase
in circulating GLP-1 was found in LPS-injected mice in agreement withMOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comprevious studies [12,13]. Since GLP-1 is secreted by EECs of the gut,
we evaluated the impact of a pro-inflammatory environment in GLP-1
secretion in colonic organoid cultures generated from GLU-Epac2-
camps mice (see Materials and Methods). Organoids were stimulated
with either regular medium (DMEM-2% FBS) or with CM collected from
peritoneal macrophages stimulated with LPS (pCM-LPS) or left un-
treated (pCM-C) for 6 h. A significant increase in GLP-1 released to the
medium was found in organoids cultured in pCM-LPS compared with
those cultured in regular medium, indicating that a pro-inflammatory
stimulus is able to trigger GLP-1 secretion both in vivo and ex vivo
(Figure 6B).
Next, we analyzed the impact of chemical inhibition of PTP1B in GLP-1
secretion in primary cultures of colonic crypts under the aforemen-
tioned pro-inflammatory conditions. Treatment of primary colonicaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 11
Figure 6: Effect of PTP1B deficiency on GLP-1 release by the gut under pro-inflammatory stimuli. A) GLP-1 serum levels from C57BL/6 J mice injected with LPS (2 mg/kg
body weight) as described in Materials and Methods. Black dots represent control animals and gray dots correspond to animals under an LPS acute pro-inflammatory stimulus.
n ¼ 4e7 mice per experimental group. *p<0.05 PTP1B WT vs PTP1B WT LPS. B) Upper panel represents GLP-1 release from colonic organoids stimulated with pCM-LPS
compared with organoids treated with pCM-C and DMEM-2%FBS. n ¼ 2 independent experiments performed in triplicate. ** p< 0.01 DMEM vs CM-LPS. Lower panel
shows colonic organoids images used in this experiment. Upper panel shows a colonic organoid with budding crypt-like domains. Bottom panel shows an organoid with mature
EEC L cells. Both images correspond to the same organoid, left image under light microscopy, right image under fluorescence microscopy. L cells (yellow fluorescence YFP) are
shown in the right image. C) GLP-1 levels measured in the culture media from colonic crypts cultured under pro-inflammatory conditions. Data are expressed as fold change
referred to control medium (DMEM alone). n ¼ 3 independent experiments performed in quadruplicate. **p < 0.01; ***p < 0.001 data referred to basal conditions; ###p < 0.001
referred to pCM-LPS. D) GLP-1 serum levels measured in animals under chow or MCD diet during 4 weeks. n ¼ 5e7 mice per experimental group. ***p < 0.001 PTP1B WT chow
vs PTP1B WT MCD; þþp < 0.01 PTP1B WT chow vs PTP1B KO chow. E) Gcg mRNA levels (encoding proglucagon) are shown as fold difference referred to the control PTP1B WT
fed a chow diet. White dots correspond to mice fed a chow diet and black dots to mice fed a MCD diet during 4 weeks. All data are expressed as mean  SEM. n ¼ 5e8 animals
per experimental group. ***p < 0.001 PTP1B WT chow vs PTP1B WT MCD ; ###p < 0.001 PTP1B KO chow vs PTP1B KO MCD.
Original Articlecultures with pCM-LPS increased GLP-1 secretion, an effect further
enhanced by the presence of a PTP1B inhibitor (Figure 6C). Of note,
GLP-1 secretion was also augmented when the PTP1B inhibitor was
directly added to the primary cultures of colonic crypts. We extended
these observations by evaluating GLP-1 levels in serum of PTP1B WT
and PTP1B KO mice after a 4-hour fast and an oral glucose challenge
as described in Materials and Methods and, as shown in Figure 6D,
they were decreased in PTP1B WT mice fed a MCD diet compared with
the levels found under a chow diet. Unexpectedly, PTP1B KO animals
exhibited lower GLP-1 levels in serum under a chow diet, but these
levels were preserved under NASH conditions. Of note, mRNA levels of
Gcg, the precursor of GLP-1, were similarly downregulated in MCD
diet-fed mice from both genotypes (Figure 6E), and no differences12 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. Tbetween genotypes were found in Dpp4 expression in the colon (data
not shown).
Since LPS or IL-6 has been shown to induce GLP-1 secretion by EECs
[12,50], we studied the impact of the mCM-LPS medium in the acti-
vation of pro-inflammatory signaling cascades in STC-1 cells. To
achieve this, STC-1 cells were stimulated with mCM-LPS for short time
periods. As depicted in Figure 7A, phosphorylation of JNK and p65
NFkB was markedly increased in STC-1 cells stimulated with mCM-
LPS. Likewise, under these conditions, a more rapid degradation of
IkBa was observed, likely reflecting an enhancement of NFkB pathway
activation. Of note, these pro-inflammatory cascades in STC-1 cells
were further enhanced by the presence of the PTP1B inhibitor in the
mCM-LPS.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Inflammatory and insulin signaling in enteroendocrine STC-1 cells stimulated with pro-inflammatory conditioned media. A) STC-1 cells were pre-incubated or
not for 2 h with the PTP1B inhibitor (20 mM) before the treatment with mCM-LPS for 5, 15, or 30 min. The dishes pretreated with the PTP1B inhibitor were used throughout the
experiment. At the end of the culture time, cells were lysed and protein extracts were analyzed by western blot with the corresponding antibodies. Vinculin was used as a loading
control. Right panel shows representative western blots. In the left panel, graphs show quantification of three independent experiments performed in duplicate. **p < 0.01 mCM-
LPS plus PTP1B inhibitor vs mCM-LPS. B) PTP1B inhibition protected against the drop of insulin signaling in EECs stimulated with pro-inflammatory conditioned medium. STC-1
cells were pre-incubated with the PTP1B inhibitor (20 mM) before the treatment with mCM-LPS or mCM-C for 16 h. Then, insulin was added for an additional 15 min. Protein
extracts were prepared, and the phosphorylation of the IR and AKT was analyzed by western blot with the antibodies against phospho-IR, phospho-AKT Ser473, phospho-AKT
Thr308, total IR, and total AKT. An anti-p85-PI3K antibody was used as a loading control. Right panel shows representative western blots. In the left panel, graphs show
quantification of three independent experiments. The different experimental conditions are indicated under the blots or graphs. Data are shown as mean  SEM. þ p < 0.05 mCM-
LPS plus PTP1B inhibitor vs mCM-LPS.
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Figure 8: mRNA expression levels of GLP-2 responsive genes in colon samples
of PTP1B WT and PTP1B KO mice under NASH conditions. A-C) Lyz (lysozyme), Kfg
(keratinocyte growth factor), and Vip (vasointestinal peptide) mRNA levels are shown as
fold change referred to the control PTP1B WT fed a chow diet. White dots correspond to
mice fed a chow diet, and black dots correspond to mice fed a MCD diet. Data are
expressed as mean  SEM. n ¼ 4e8 animals per experimental group. þp< 0.05;
þþp < 0.01 PTP1B WT chow diet vs PTP1B KO chow diet.
Original ArticleIt has been reported that insulin via IR-mediated signaling stimulates
proglucagon gene expression and, subsequently, the secretion of GLP-
1 [51,52]. Since PTP1B dephosphorylates and switches off IR tyrosine
kinase activity, we analyzed the impact of PTP1B inhibition in insulin
signaling in STC-1 cells. Supplmentary Fig. 2A shows that the pre-
treatment with a selective PTP1B inhibitor for 2 h before insulin
stimulation further enhanced IR and AKT (Ser473 and Thr308 residues)
phosphorylation. A step further, insulin signaling was decreased by the
presence of the pro-inflammatory environment of the mCM-LPS
(Supplementary Fig. 2B) and, importantly, PTP1B inhibition increased
insulin signaling even in these pro-inflammatory conditions
(Figure 7B). Altogether, these results suggest that PTP1B plays a role in
GLP-1 secreting EECs in the context of inflammation and IR-mediated
signaling.
In addition to GLP-1, GLP-2 has also a beneficial effect on gut mucosal
integrity as an intestinotrophic factor mainly by stimulating crypt cell
proliferation, an effect mediated by the intestinal IGF-1-IGF-1R system
[53e55]. Because PTP1B deficiency enhances IGF-1R-mediated ef-
fects in a cell autonomous manner [56], we hypothesized that
constitutive enhancement of GLP-2 effects would contribute to the
better preservation of the gut barrier integrity in PTP1B KO mice. As
depicted in Figure 8AeC, constitutive expression levels of Lyz
(encoding lysozyme) and Kgf (encoding keratinocyte growth factor),
two GLP-2 responsive genes [57], were significantly elevated in colon
samples from PTP1B KO mice under basal conditions (chow diet)
together with a trend toward elevation of Vip (encoding vasoactive
intestinal peptide) mRNA compared with the expression levels of
PTP1B WT mice.
4. DISCUSSION
This work has been focused on the study of gut barrier alterations
during NASH, a chronic liver disease characterized by a robust pro-
inflammatory component, as well as in deciphering a previously un-
known role of PTP1B in this process. Since PTP1B displays cellular-
specific dual effects, on the one hand, promoting insulin resistance
and susceptibility to cell death in non-immune cells such as hepato-
cytes [20,58] and, on the other, inhibiting the pro-inflammatory re-
sponses in immune cells [21e24,59], the research on the duality of
actions of PTP1B in gut cells (immune and non-immune) during NASH-
mediated inflammation is relevant. Overall, our results have showed
that both diversity and gut microbial composition are different between
mice with a healthy liver and mice with NASH. In addition, some NASH-
mediated alterations in gut microbiota are different in PTP1B KO and
PTP1B WT mice, as will be discussed following.
It is well known that microbiota diversity is essential to maintain the
stability and efficiency of this dynamic micro ecosystem [60]. Our
results show that the a-diversity, measured by Shannon index, is lower
during MCD diet-induced NASH. Furthermore, the unweighted UniFrac
PCoA plot analysis reflects a clustering of the microbial populations
from animals fed a MCD diet far away from that of the controls fed a
chow diet, confirming that MCD diet-induced NASH alters intestinal
microbial populations. Moreover, taxonomy analysis showed that the
main changes between the four experimental groups (PTP1B WT chow,
PTP1B WT MCD, PTP1B KO chow, and PTP1B KO MCD) are due to
NASH as a disease.
In PTP1B WT mice under a MCD diet, the abundance of Firmicutes
increased, whereas a marked decrease was observed in Bacteroidetes
leading to a higher F/B ratio. By contrast, we did not find changes in
MCD diet-fed PTP1B KO mice, either in F/B ratio or in Bacteroidetes
and Firmicutes abundance. In this regard, it has been previously14 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. Tdescribed that patients with NASH have a significantly lower proportion
of Bacteroidetes compared with healthy controls or those with NAFLD
[61]; whereas, decreased F/B ratio was found in patients with in-
flammatory bowel disease [62]. Moreover, patients with NASH under a
probiotic-supplemented diet exhibit a higher level of Bacteroidetes in
parallel to a decrease in intrahepatic triglyceride content [8].
Our data also show an increase in the families Porphyromonadaceae
(and the corresponding genus Parabacteroides), Erysipelotrichaceae
(and the corresponding genus Allobaculum), and Rikenellaceae in mice
receiving a MCD diet for 4 weeks. In addition, an increase in the
abundance of family Turicibacteraceae (and the corresponding genus
Turicibacter) was also observed, but only in PTP1B WT animals. These
variations agree with observations from other studies in mice under a
MCD diet or in patients with NASH [28,63e65]. Families Rikenellaceaehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Turicibacteraceae are known to be associated with inflammatory
states [28] and might contribute to gut inflammation in mice receiving
a MCD diet. Conversely, a significant decrease of families S24-7,
Dehalobacteriaceae, Mogibacteriaceae, Lactobacillae, Lachnospir-
aceae, and genera Adlercreutzia, Lactobacillus, Roseburia, and
Desulfovibrio was found in mice with NASH. In particular, a low
presence of Dehalobacteriaceae was detected only in PTP1B WT mice,
and the same was observed for Lachnospiraceae; but, its genus
Roseburia decreased in mice from both phenotypes. Of special interest
is the decrease observed in MCD diet-fed mice of Lactobacillus and
Roseburia, two beneficial organisms producing lactate and butyrate,
respectively. Lactate-producing bacteria promote lactate-converting
organisms, such as Roseburia, that produce butyrate favoring the
abundance of Lactobacilli, thereby contributing to the maintenance of
the anti-inflammatory effects of these microorganisms [28,66,67]. The
observed decrease in genus Desulfovibrio with the MCD diet should
cause a lower production of H2S in the gut, a compound that has been
related to regulation of epithelial mucus production and decrease of
systemic inflammation [65,68]. Likewise, a lower abundance of
Adlercreutzia and Dehalobacteriaceae might be related to altered lipid
and glucose metabolism. In this regard, Adlercreutzia is characterized
by its ability to produce equol, which binds to the G-protein-coupled
estrogen receptor (GPER) and improves glucose tolerance [69].
Conversely, Dehalobateriaceae has been reported to decrease in sit-
uations of hepatic lipid accumulation induced by environmental
chemicals [70]. Notably, two marked alterations are observed only in
PTP1B KO mice. First, at the phylum level, TM7 relative levels
decreased in these mice during NASH. Phylum TM7 has been
described as a potential immunomodulatory due to its ability to inhibit
TNFa production in macrophages [71,72] and, consequently, its
decrease could be associated with the exacerbation of inflammation in
NAFLD in PTP1B KO mice [25]. Because PTP1B KO mice present a
constitutive pro-inflammatory phenotype, it is possible to speculate
that the lower presence of phylum TM7 might play a role in their
immune responses during NASH progression. Second, the LPS-
producing genus Prevotella increases in PTP1B KO mice under a
MCD diet. This finding is somehow unexpected, since PTP1B KO mice
under a MCD diet show a lower level of circulating LPS than WT an-
imals. It is worth noting that some changes in microbiota described in
the MCD diet-induced NASH, such as decreased level of Lactobacillus
and Roseburia and increased level of Prevotella, are similar to those
reported in individuals with lean NASH [73], many of them with
malnutrition (choline deficiency) or genetic impairment of phosphati-
dylcholine synthesis [74].
A step forward, the PICRUSt functional approach showed that a MCD
diet shifts metabolic pathways of the microbial community toward a
reduction in genes involved in metabolism of cofactors and vitamins
and energy balance in PTP1B WT, but not in PTP1B KO mice, pointing
to an impact of PTP1B deletion in the changes of bacterial metabolism
under the NASH condition. Of relevance, when we compared both
genotypes, gut microbiota from PTP1B WT mice fed a MCD diet
overexpressed genes involved in the synthesis of secondary bile acids,
whereas PTP1B KO mice exhibited an increase in genes linked to
propionate metabolism. Since propionate (a short-chain fatty acid) is
considered to be a health promoting microbial metabolite that pos-
sesses biological activity at the intestine and intestinal epithelium level
[75], these differences likely associate PTP1B WT mice with a more
harmful microbiota compared with their counterparts lacking PTP1B.
There is a growing interest in revealing the function of bile acids during
NASH and their possible role in the onset and progression of this
disease. In agreement with the work of Puri and co-workers [76], weMOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
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NASH. It is known that primary bile acid synthesis is modulated by gut
microbiota through the regulation of key enzymes of this metabolic
pathway such as CYP7A1. Related to this, ileal FXR activation by its
agonist CDCA leads to CYP7A1 inhibition [77] and, therefore, de-
creases bile acid synthesis. During NASH, CA levels are much higher
than CDCA levels and, as a result, FXR activation by CDCA is reduced,
thereby increasing bile acid synthesis. Thus, the lower levels of CA
found in serum from PTP1B KO mice during NASH point to a lower bile
acid synthesis, which was manifested by decreased amounts of CA,
CDCA, and UDCA. These data are reinforced by increased expression of
the Nr1h4 gene (coding FXR protein) observed in the gut of MCD diet-
fed PTP1B KO mice compared with their PTP1B WT counterparts. In
addition, as we remarked previously, PICRUSt predicted that gut
microbiome from PTP1B WT mice fed a MCD diet is enriched in genes
for secondary bile acid biosynthesis compared with PTP1B KO mice,
and this could be the reason of the lower plasma levels of TDCA during
NASH found in mice lacking PTP1B.
Although a number of studies have addressed the molecular mecha-
nisms involved in the progression of NAFLD toward NASH, little is
known about how the intestine is affected by this inflammatory dis-
ease. A recent study [28] has reported the beneficial effect of butyrate
on MCD diet-induced gut barrier dysfunction and inflammation in the
liver. A previous clinical study [78] demonstrated that both intestinal
permeability and alterations in gut microbiota were increased in pa-
tients with NAFLD. In the present study, we found that colonic edema
and, thus, colonic inflammation, was significantly enhanced only in
PTP1B KO mice with NASH, suggesting exacerbated pro-inflammatory
responses in this genotype as we previously reported [24]. Moreover,
the presence of inflammatory infiltrates in the colonic mucosa together
with a marked increase in the expression levels of inflammatory
markers such as Ifng and Nos2 were found in PTP1B KO animals fed a
MCD diet compared with PTP1B WT mice. Of note, PTP1B KO mice fed
a chow diet showed increased expression levels of Cd3g and GzmB
compared with PTP1B WT mice, reinforcing the fact that PTP1B KO
mice exhibit an intrinsic pro-inflammatory susceptibility, which is
exacerbated after NASH induction. Taking into account that PTP1B is a
negative modulator of key immune signaling cascades [24], our results
suggesting that PTP1B deficiency likely facilitates the activation of
macrophages (through increasing Nos2) and T lymphocytes (through
Ifng, Cd3g and GzmB) in the gut are in line with data previously re-
ported by our laboratory and others in different inflammatory contexts
[24,79]. Because NASH concurs with a systemic pro-inflammatory
environment [80], the enhancement of gut inflammation in PTP1B
KO mice is somehow expected due to the dynamic cross-talk in the
gut-to-liver axis.
To obtain further insights on differential gut barrier disruption in PTP1B
WT and PTP1B KO mice with NASH, we measured their intestinal
permeability by a FITC-dextran assay, which showed major flux of this
fluorescent compound and, thus, major leakage in PTP1B WT mice.
Similar results were obtained by the analysis of serum endotoxin
content, confirming a disruption in the gut barrier function by the MCD
diet and, importantly, a partial protection in PTP1B KO mice. We also
explored gut barrier permeability in a cellular autonomous manner and
found decreased TEER values in Caco-2 cells and, thus, disrupted
barrier integrity under pro-inflammatory culture conditions in agree-
ment with the work of Moran and co-workers showing decreased TEER
in Caco-2 cells cultured with TNFa [81]. However, no differences were
observed between Caco-2 cells with silenced Ptpn1 and the controls
(shScrb). Taking into account that TEER measurement allows the study
of barrier integrity in an epithelial monolayer depending only on theaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 15
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deficiency in the epithelial cells of the gut might not affect permeability
in a relevant way. By contrast, the analysis of the tight junction protein
ZO-1 in colon sections showed a better preservation of the gut barrier
features in PTP1B KO mice fed a MCD diet. Thus, the results of the
in vivo NASH model in which PTP1B deficiency confers protection
against gut barrier disruption triggered by pro-inflammatory stimuli
strongly suggest that environmental factors such as the aforemen-
tioned gut microbiota diversity rather than the gut epithelial cells may
have a major contribution in maintaining the gut barrier integrity under
this pathologic condition.
Recent findings have expanded the classical concept of enteroendocrine
L cell biology toward sensors of inflammatory stimuli and compromised
mucosal integrity, thereby linking GLP-1 secretion to gut inflammation.
Yusta and co-workers showed that binding of GLP-1 to its receptor in
IELs switches the pattern of the inflammatory response [13]. In a recent
study, Lebrun and co-workers [12] reported increases in GLP-1 levels in
circulation by LPS administration as well as in a dextran sulfate sodium-
and ischemia/reperfusion-induced colitis model in mice, this effect
being dependent on TLR4. A step further, the same study showed el-
evations in GLP-1 in human healthy volunteers receiving a single in-
jection of LPS and patients subjected to ischemia/reperfusion in a jejunal
segment during a pancreaticoduodenectomy. Moreover, Keller and co-
workers [82] showed increased release of GLP-1 in patients with in-
flammatory bowel disease. Despite the effects of acute pro-
inflammatory stimuli or severe gut inflammation in triggering GLP-1
release to the circulation, our results showed that under a mild
chronic pro-inflammatory environment (i.e. MCD diet), PTP1B WT ani-
mals had reduced circulating GLP-1 levels in response to an oral glucose
challenge. A possible explanation for such effect could be supported by
the existence of a cross-talk between EECs and IELs aimed to counteract
elevated inflammation, although MCD diet-fed PTP1B WT mice might
not have reached enough inflammatory thresholds to activate this
compensatory mechanism through time. In line with these data, a hu-
man study reported reduced peak (15 min) GLP-1 concentrations in a
cohort of 52 non-diabetic patients with NAFLD (including simple stea-
tosis and NASH) compared with controls, as well as total GLP-1
secretion in an oral glucose tolerance test [83]. Interestingly, PTP1B
KOmice that already showed lower glucose-triggered GLP-1 responses
on a chow diet were protected against the decrease of this incretin under
a MCD diet. We speculate that the reduced GLP-1 responses found in
PTP1B KO animals on a chow diet would prevent excessive postprandial
insulin excursions in these systemic hypoinsulinemic and insulin-
hypersensitive animals [19,84] to avoid excessive hypoglycemia.
Future research could unravel differences in the amount of IELs between
PTP1B WT and PTP1B KO mice.
To further investigate the role of PTP1B in GLP-1 release by the gut
under pro-inflammatory conditions as previously reported [12,13], we
performed in vitro studies in EECs, colonic organoids, and primary
cultures of colonic crypts. Our results showed for the first time on the
one hand, an effect of PTP1B inhibition by enhancing the pro-
inflammatory signaling cascades triggered by the mCM-LPS (JNK,
NFkB) in STC-1 cells, reinforcing our experimental evidence on the
impact of this phosphatase in the interplay between immune (likely IELs)
and EECs in the gut and, on the other, an unknown role of this phos-
phatase as a negative modulator of insulin signaling (IR, Akt) in EECs
cells under basal or pro-inflammatory conditions. A step further, in a
more physiological model using primary cultures of colonic crypts, we
found a significant increase in GLP-1 release on treatment with the pro-
inflammatory media and, more importantly, this effect was further
increased in the presence of the PTP1B inhibitor that, as previously16 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. Tmentioned, increased the pro-inflammatory signaling cascades in EECs.
Altogether, these results led us to suggest that PTP1B deficiency might
affect both IELs and EECs by enhancing pro-inflammatory and insulin
signaling, respectively, thereby boosting GLP-1 secretion. However, a
limitation of the present study is the use of global PTP1B-deficient mice
and, in this regard, future research will be needed to characterize the
outcome of deficiency of this phosphatase in different gut cell types.
The results of the present study are apparently contradictory with our
previous data [25] showing accelerated NASH in PTP1B KO mice on a
MCD diet due to enhanced immune responses in the liver. The protective
mechanism in the intestine reported here seems to be tissue-specific and
could be explained by the maintenance of GLP-1 levels in MCD diet-fed
PTP1B KOmice that elicit an anti-inflammatory protective effect targeting
IELs (as proposed by Yusta and co-workers [13]) and probably other gut
cell types, thereby preserving gut barrier permeability. In contrast, the
severe hepatic phenotype of PTP1BKOmice on aMCDdiet reported in our
previous manuscript [25] likely reflects a profound inflammation within
the liver beyond endotoxemia that results from the enhancement of pro-
inflammatory signaling cascades in immune cells of the liver, either
resident or recruited, on NASH insult.
GLP-1 and GLP-2 are simultaneously produced via posttranslational
processing of proglucagon by prohormone convertase 1/3 and co-
secreted from intestinal L cells [85]. In the context of gut inflamma-
tion, Lebrun and co-workers showed increases in plasma GLP-2 in
mice receiving an acute injection of LPS or subjected to intestinal
ischemia/reperfusion [12]. In this regard, we found higher constitutive
expression of GLP-2 sensitive genes in colon samples from PTP1B KO
mice. These data are relevant since gut epithelial IGF-1R signaling has
been shown to mediate the effects of GLP-2 in the proliferation of the
gut crypts [55], and it is plausible that PTP1B-deficiency might confer
increased GLP-2 secretion together with IGF-1R-mediated sensitivity in
the gut as occurs in pancreatic beta cells [56,86], as demonstrated by
the greater depth of the colonic crypts in PTP1B KO mice, thereby
favoring gut mucosal integrity. Another possible explanation for the
better preservation of the gut barrier in PTP1B KO mice is based on the
requirement of insulin for the maintenance of normal rates of protein
synthesis in the mucosa of the small intestine, an essential component
of the remodeling process during damage [87]. Thus, the decrease in
the synthesis rate of small intestine mucosa under hypoinsulinemia in
MCD-induced NASH might be attenuated in PTP1B KO mice due to
their hypersensitivity to insulin.
5. CONCLUSIONS
Taking all the results together, this study has identified a protective role
of PTP1B deficiency against the shift in gut microbiome during NASH
that was accompanied with less gut barrier permeability, preserved
GLP-1 levels under a pro-inflammatory environment, and a potential
sensitivity to GLP-2. Further investigation is required to identify the
accurate mechanisms responsible for the ameliorated phenotype of
PTP1B KO mice in the gut during this liver pathology with a possible
therapeutic value.
FUNDING
This work was funded by grants SAF2015-65267-R (MINECO/FEDER,
UE), RTI2018-094052-B-100 (MCI/AEI/FEDER, UE), S2010/BMD-2423,
S2017/BMD-3684 (Comunidad de Madrid, Spain), CIBERdem, CIBERhed
and PI 16/02096 (ISCIII, Spain). We also acknowledge grants H2020
Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236,
European Commission), Spanish Ministry of Education-MECD (FPU13/his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
05802 grant to C.R) and Fundación Ramón Areces (to A.M.V.). CBMSO is
recipient of institutional aid fromFundación Ramón Areces. VBL, FMGand
FR received funding from a Wellcome Trust joint investigator award
(106262/Z/14/Z and 106263/Z/14/Z) and a joint MRC programme within
the Metabolic Diseases Unit (MRC_MC_UU_12012/3), United Kingdom.
VBL received a project support grant from the Society for Endocrinology,
United Kingdom. The MRL Histology and Biochemistry Assay Lab Core
facilities received funding from the MRC Metabolic Diseases Unit
[MRC_MC_UU_12012/5] and the Imaging Core through a Wellcome
Trust Strategic Award [100574/Z/12/Z], United Kingdom.
AUTHOR CONTRIBUTIONS
C.R.; participated in study design, acquisition, analysis, interpretation
of data and writing of the manuscript; M.P and J.J G-R performed
analysis of gut permeability; V.B.L performed the organoid studies; I.
G-M and R.A performed the signaling studies; P.SeS and M.V. T-L
contributed to gut characterization; J.S, J.R and C.B contributed to the
analysis of bile acids; L.M; F.M.G; F.R; L.G.G contributed to supervision
of the work and scientific discussion; A.M.V and J.M.C participted in
design and coordination of the study and wrote the manuscript. All
authors revised and approved the final manuscript.
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at https://doi.org/10.1016/j.
molmet.2020.01.018.
REFERENCES
[1] Byrne, C.D., Targher, G., 2015. NAFLD: a multisystem disease. Journal of
Hepatology 62(1 Suppl):S47eS64.
[2] Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., 2013. From
NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nature
Reviews Gastroenterology & Hepatology 10(11):627e636.
[3] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K.,
et al., 2012. The diagnosis and management of non-alcoholic fatty liver dis-
ease: practice guideline by the American Gastroenterological Association,
American Association for the Study of Liver Diseases, and American College of
Gastroenterology. Gastroenterology 142(7):1592e1609.
[4] Henao-Mejia, J., Elinav, E., Thaiss, C.A., Flavell, R.A., 2013. The intestinal
microbiota in chronic liver disease. Advances in Immunology 117:73e97.
[5] Hoyles, L., Fernandez-Real, J.M., Federici, M., Serino, M., Abbott, J.,
Charpentier, J., et al., 2018. Molecular phenomics and metagenomics of hepatic
steatosis in non-diabetic obese women. Nature Medicine 24(7):1070e1080.
[6] Betrapally, N.S., Gillevet, P.M., Bajaj, J.S., 2016. Changes in the intestinal
microbiome and alcoholic and nonalcoholic liver diseases: causes or effects?
Gastroenterology 150(8):1745e1755 e3.
[7] Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., et al., 2017.
Gut microbiome-based metagenomic signature for non-invasive detection of
advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metabolism
25(5):1054e1062 e5.
[8] Pachikian, B.D., Essaghir, A., Demoulin, J.B., Catry, E., Neyrinck, A.M.,
Dewulf, E.M., et al., 2013. Prebiotic approach alleviates hepatic steatosis:
implication of fatty acid oxidative and cholesterol synthesis pathways. Mo-
lecular Nutrition & Food Research 57(2):347e359.
[9] Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K.,
Mandrekar, P., et al., 2009. VSL#3 probiotic treatment attenuates fibrosis
without changes in steatohepatitis in a diet-induced nonalcoholic steatohe-
patitis model in mice. Hepatology 49(3):989e997.MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.com[10] Wagnerberger, S., Spruss, A., Kanuri, G., Stahl, C., Schroder, M., Vetter, W.,
et al., 2013. Lactobacillus casei Shirota protects from fructose-induced liver
steatosis: a mouse model. The Journal of Nutritional Biochemistry 24(3):531e
538.
[11] Sternini, C., Anselmi, L., Rozengurt, E., 2008. Enteroendocrine cells: a site of
’taste’ in gastrointestinal chemosensing. Current Opinion in Endocrinology
Diabetes and Obesity 15(1):73e78.
[12] Lebrun, L.J., Lenaerts, K., Kiers, D., Pais de Barros, J.P., Le Guern, N.,
Plesnik, J., et al., 2017. Enteroendocrine L cells sense LPS after gut barrier
injury to enhance GLP-1 secretion. Cell Reports 21(5):1160e1168.
[13] Yusta, B., Baggio, L.L., Koehler, J., Holland, D., Cao, X., Pinnell, L.J., et al.,
2015. GLP-1R Agonists modulate enteric immune responses through the in-
testinal intraepithelial lymphocyte GLP-1R. Diabetes 64(7):2537e2549.
[14] Insuela, D.B.R., Carvalho, V.F., 2017. Glucagon and glucagon-like peptide-1 as
novel anti-inflammatory and immunomodulatory compounds. European Jour-
nal of Pharmacology 812:64e72.
[15] Bugianesi, E., Moscatiello, S., Ciaravella, M.F., Marchesini, G., 2010. Insulin
resistance in nonalcoholic fatty liver disease. Current Pharmaceutical Design
16(17):1941e1951.
[16] Salmeen, A., Andersen, J.N., Myers, M.P., Tonks, N.K., Barford, D., 2000.
Molecular basis for the dephosphorylation of the activation segment of the
insulin receptor by protein tyrosine phosphatase 1B. Molecular Cell 6(6):
1401e1412.
[17] Seely, B.L., Staubs, P.A., Reichart, D.R., Berhanu, P., Milarski, K.L.,
Saltiel, A.R., et al., 1996. Protein tyrosine phosphatase 1B interacts with the
activated insulin receptor. Diabetes 45(10):1379e1385.
[18] Zabolotny, J.M., Bence-Hanulec, K.K., Stricker-Krongrad, A., Haj, F., Wang, Y.,
Minokoshi, Y., et al., 2002. PTP1B regulates leptin signal transduction in vivo.
Developmental Cell 2(4):489e495.
[19] Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A.L.,
et al., 1999. Increased insulin sensitivity and obesity resistance in mice lacking
the protein tyrosine phosphatase-1B gene. Science 283(5407):1544e1548.
[20] Gonzalez-Rodriguez, A., Mas-Gutierrez, J.A., Mirasierra, M., Fernandez-
Perez, A., Lee, Y.J., Ko, H.J., et al., 2012. Essential role of protein tyrosine
phosphatase 1B in obesity-induced inflammation and peripheral insulin
resistance during aging. Aging Cell 11(2):284e296.
[21] Aoki, N., Matsuda, T., 2000. A cytosolic protein-tyrosine phosphatase PTP1B
specifically dephosphorylates and deactivates prolactin-activated STAT5a and
STAT5b. Journal of Biological Chemistry 275(50):39718e39726.
[22] Lu, X., Malumbres, R., Shields, B., Jiang, X., Sarosiek, K.A., Natkunam, Y.,
et al., 2008. PTP1B is a negative regulator of interleukin 4-induced STAT6
signaling. Blood 112(10):4098e4108.
[23] Myers, M.P., Andersen, J.N., Cheng, A., Tremblay, M.L., Horvath, C.M.,
Parisien, J.P., et al., 2001. TYK2 and JAK2 are substrates of protein-tyrosine
phosphatase 1B. Journal of Biological Chemistry 276(51):47771e47774.
[24] Traves, P.G., Pardo, V., Pimentel-Santillana, M., Gonzalez-Rodriguez, A.,
Mojena, M., Rico, D., et al., 2014. Pivotal role of protein tyrosine phosphatase
1B (PTP1B) in the macrophage response to pro-inflammatory and anti-
inflammatory challenge. Cell Death & Disease 5:e1125.
[25] Gonzalez-Rodriguez, A., Valdecantos, M.P., Rada, P., Addante, A., Barahona, I.,
Rey, E., et al., 2018. Dual role of protein tyrosine phosphatase 1B in the
progression and reversion of non-alcoholic steatohepatitis. Molecular Meta-
bolism 7:132e146.
[26] Haczeyni, F., Yeh, M.M., Ioannou, G.N., Leclercq, I.A., Goldin, R., Dan, Y.Y.,
et al., 2018. Mouse models of non-alcoholic steatohepatitis: a reflection on
recent literature. Journal of Gastroenterology and Hepatology 33(7):1312e
1320.
[27] Oz, H.S., Chen, T.S., Neuman, M., 2008. Methionine deficiency and hepatic
injury in a dietary steatohepatitis model. Digestive Diseases and Sciences
53(3):767e776.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 17
Original Article[28] Ye, J., Lv, L., Wu, W., Li, Y., Shi, D., Fang, D., et al., 2018. Butyrate protects
mice against methionine-choline-deficient diet-induced non-alcoholic steato-
hepatitis by improving gut barrier function, attenuating inflammation and
reducing endotoxin levels. Frontiers in Microbiology 9:1967.
[29] Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., et al.,
2013. Evaluation of general 16S ribosomal RNA gene PCR primers for classical
and next-generation sequencing-based diversity studies. Nucleic Acids
Research 41(1):e1.
[30] Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D.,
Costello, E.K., et al., 2010. QIIME allows analysis of high-throughput com-
munity sequencing data. Nature Methods 7(5):335e336.
[31] Lozupone, C., Knight, R., 2005. UniFrac: a new phylogenetic method for
comparing microbial communities. Applied and Environmental Microbiology
71(12):8228e8235.
[32] Langille, M.G., Zaneveld, J., Caporaso, J.G., McDonald, D., Knights, D.,
Reyes, J.A., et al., 2013. Predictive functional profiling of microbial commu-
nities using 16S rRNA marker gene sequences. Nature Biotechnology 31(9):
814e821.
[33] Roman, I.D., Cano-Martinez, D., Lobo, M.V., Fernandez-Moreno, M.D., Her-
nandez-Breijo, B., Sacristan, S., et al., 2017. Infliximab therapy reverses the
increase of allograft inflammatory factor-1 in serum and colonic mucosa of
rats with inflammatory bowel disease. Biomarkers 22(2):133e144.
[34] Alnouti, Y., Csanaky, I.L., Klaassen, C.D., 2008. Quantitative-profiling of bile
acids and their conjugates in mouse liver, bile, plasma, and urine using LC-
MS/MS. Journal of Chromatography B Analytical Technologies in the
Biomedical and Life Sciences 873(2):209e217.
[35] Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N.,
Stange, D.E., et al., 2009. Single Lgr5 stem cells build crypt-villus structures
in vitro without a mesenchymal niche. Nature 459(7244):262e265.
[36] Goldspink, D.A., Lu, V.B., Billing, L.J., Larraufie, P., Tolhurst, G., Gribble, F.M.,
et al., 2018. Mechanistic insights into the detection of free fatty and bile acids
by ileal glucagon-like peptide-1 secreting cells. Molecular Metabolism 7:90e
101.
[37] Reimann, F., Habib, A.M., Tolhurst, G., Parker, H.E., Rogers, G.J.,
Gribble, F.M., 2008. Glucose sensing in L cells: a primary cell study. Cell
Metabolism 8(6):532e539.
[38] Kim, B.R., Shin, J., Guevarra, R., Lee, J.H., Kim, D.W., Seol, K.H., et al., 2017.
Deciphering diversity indices for a better understanding of microbial com-
munities. Journal of Microbiology and Biotechnology 27(12):2089e2093.
[39] Wahlstrom, A., Sayin, S.I., Marschall, H.U., Backhed, F., 2016. Intestinal
crosstalk between bile acids and microbiota and its impact on host meta-
bolism. Cell Metabolism 24(1):41e50.
[40] Chiang, J.Y.L., Ferrell, J.M., 2018. Bile acid metabolism in liver pathobiology.
Gene Expression 18(2):71e87.
[41] Artursson, P., Ungell, A.L., Lofroth, J.E., 1993. Selective paracellular perme-
ability in two models of intestinal absorption: cultured monolayers of human
intestinal epithelial cells and rat intestinal segments. Pharmaceutical Research
10(8):1123e1129.
[42] Rodriguez-Feo, J.A., Puerto, M., Fernandez-Mena, C., Verdejo, C., Lara, J.M.,
Diaz-Sanchez, M., et al., 2015. A new role for reticulon-4B/NOGO-B in the
intestinal epithelial barrier function and inflammatory bowel disease. American
Journal of Physiology - Gastrointestinal and Liver Physiology 308(12):G981e
G993.
[43] Cibor, D., Domagala-Rodacka, R., Rodacki, T., Jurczyszyn, A., Mach, T.,
Owczarek, D., 2016. Endothelial dysfunction in inflammatory bowel diseases:
pathogenesis, assessment and implications. World Journal of Gastroenterology
22(3):1067e1077.
[44] Kitajima, S., Takuma, S., Morimoto, M., 2000. Histological analysis of murine
colitis induced by dextran sulfate sodium of different molecular weights.
Experimental Animals 49(1):9e15.18 MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. T[45] Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J., 2012.
Ulcerative colitis. Lancet 380(9853):1606e1619.
[46] Machado, M.V., Michelotti, G.A., Xie, G., Almeida Pereira, T., Boursier, J.,
Bohnic, B., et al., 2015. Mouse models of diet-induced nonalcoholic steato-
hepatitis reproduce the heterogeneity of the human disease. PloS One 10(5):
e0127991.
[47] Montbarbon, M., Pichavant, M., Langlois, A., Erdual, E., Maggiotto, F., Neut, C.,
et al., 2013. Colonic inflammation in mice is improved by cigarette smoke
through iNKT cells recruitment. PloS One 8(4):e62208.
[48] Motavallian-Naeini, A., Andalib, S., Rabbani, M., Mahzouni, P., Afsharipour, M.,
Minaiyan, M., 2012. Validation and optimization of experimental colitis in-
duction in rats using 2, 4, 6-trinitrobenzene sulfonic acid. Research in Phar-
maceutical Sciences 7(3):159e169.
[49] Peterson, L.W., Artis, D., 2014. Intestinal epithelial cells: regulators of barrier
function and immune homeostasis. Nature Reviews Immunology 14(3):141e
153.
[50] Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A.M., Baggio, L.L.,
Meier, D.T., et al., 2011. Interleukin-6 enhances insulin secretion by
increasing glucagon-like peptide-1 secretion from L cells and alpha cells.
Nature Medicine 17(11):1481e1489.
[51] Lim, G.E., Huang, G.J., Flora, N., LeRoith, D., Rhodes, C.J., Brubaker, P.L.,
2009. Insulin regulates glucagon-like peptide-1 secretion from the enter-
oendocrine L cell. Endocrinology 150(2):580e591.
[52] Yi, F., Sun, J., Lim, G.E., Fantus, I.G., Brubaker, P.L., Jin, T., 2008. Cross talk
between the insulin and Wnt signaling pathways: evidence from intestinal
endocrine L cells. Endocrinology 149(5):2341e2351.
[53] Benjamin, M.A., McKay, D.M., Yang, P.C., Cameron, H., Perdue, M.H., 2000.
Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both
transcellular and paracellular pathways in the mouse. Gut 47(1):112e119.
[54] Cameron, H.L., Perdue, M.H., 2005. Stress impairs murine intestinal barrier
function: improvement by glucagon-like peptide-2. Journal of Pharmacology
and Experimental Therapeutics 314(1):214e220.
[55] Dong, C.X., Zhao, W., Solomon, C., Rowland, K.J., Ackerley, C., Robine, S.,
et al., 2014. The intestinal epithelial insulin-like growth factor-1 receptor links
glucagon-like peptide-2 action to gut barrier function. Endocrinology 155(2):
370e379.
[56] Fernandez-Ruiz, R., Vieira, E., Garcia-Roves, P.M., Gomis, R., 2014. Protein
tyrosine phosphatase-1B modulates pancreatic beta-cell mass. PloS One 9(2):
e90344.
[57] Yusta, B., Holland, D., Waschek, J.A., Drucker, D.J., 2012. Intestinotrophic
glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and
growth factor-dependent pathways independent of the vasoactive intestinal
peptide gene in mice. Endocrinology 153(6):2623e2632.
[58] Sangwan, V., Paliouras, G.N., Cheng, A., Dube, N., Tremblay, M.L., Park, M.,
2006. Protein-tyrosine phosphatase 1B deficiency protects against Fas-
induced hepatic failure. Journal of Biological Chemistry 281(1):221e228.
[59] Heinonen, K.M., Dube, N., Bourdeau, A., Lapp, W.S., Tremblay, M.L., 2006.
Protein tyrosine phosphatase 1B negatively regulates macrophage develop-
ment through CSF-1 signaling. Proceedings of the National Academy of Sci-
ences of the United States of America 103(8):2776e2781.
[60] de Almada, C.N., Nunes de Almada, C., Martinez, R.C., Sant’Ana Ade, S.,
2015. Characterization of the intestinal microbiota and its interaction with
probiotics and health impacts. Applied Microbiology and Biotechnology 99(10):
4175e4199.
[61] Mouzaki, M., Comelli, E.M., Arendt, B.M., Bonengel, J., Fung, S.K.,
Fischer, S.E., et al., 2013. Intestinal microbiota in patients with nonalcoholic
fatty liver disease. Hepatology 58(1):120e127.
[62] Sokol, H., Seksik, P., Furet, J.P., Firmesse, O., Nion-Larmurier, I.,
Beaugerie, L., et al., 2009. Low counts of Faecalibacterium prausnitzii in colitis
microbiota. Inflammatory Bowel Diseases 15(8):1183e1189.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
[63] Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., et al.,
2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and
obesity. Nature 482(7384):179e185.
[64] Wong, V.W., Tse, C.H., Lam, T.T., Wong, G.L., Chim, A.M., Chu, W.C., et al.,
2013. Molecular characterization of the fecal microbiota in patients with
nonalcoholic steatohepatitis-a longitudinal study. PloS One 8(4):e62885.
[65] Ye, J.Z., Li, Y.T., Wu, W.R., Shi, D., Fang, D.Q., Yang, L.Y., et al., 2018.
Dynamic alterations in the gut microbiota and metabolome during the devel-
opment of methionine-choline-deficient diet-induced nonalcoholic steatohe-
patitis. World Journal of Gastroenterology 24(23):2468e2481.
[66] Tamanai-Shacoori, Z., Smida, I., Bousarghin, L., Loreal, O., Meuric, V.,
Fong, S.B., et al., 2017. Roseburia spp.: a marker of health? Future Micro-
biology 12:157e170.
[67] Wang, Y., Gu, Y., Fang, K., Mao, K., Dou, J., Fan, H., et al., 2018. Lactobacillus
acidophilus and Clostridium butyricum ameliorate colitis in murine by
strengthening the gut barrier function and decreasing inflammatory factors.
Beneficial Microbes, 1e14.
[68] Wallace, J.L., Motta, J.P., Buret, A.G., 2018. Hydrogen sulfide: an agent of
stability at the microbiome-mucosa interface. American Journal of Physiology -
Gastrointestinal and Liver Physiology 314(2):G143eG149.
[69] Sharma, G., Hu, C., Brigman, J.L., Zhu, G., Hathaway, H.J., Prossnitz, E.R.,
2013. GPER deficiency in male mice results in insulin resistance, dyslipidemia,
and a proinflammatory state. Endocrinology 154(11):4136e4145.
[70] Lai, K.P., Ng, A.H., Wan, H.T., Wong, A.Y., Leung, C.C., Li, R., et al., 2018.
Dietary exposure to the environmental chemical, PFOS on the diversity of gut
microbiota, associated with the development of metabolic syndrome. Frontiers
in Microbiology 9:2552.
[71] He, X., McLean, J.S., Edlund, A., Yooseph, S., Hall, A.P., Liu, S.Y., et al., 2015.
Cultivation of a human-associated TM7 phylotype reveals a reduced genome
and epibiotic parasitic lifestyle. Proceedings of the National Academy of Sci-
ences of the United States of America 112(1):244e249.
[72] Liang, Y., Liang, S., Zhang, Y., Deng, Y., He, Y., Chen, Y., et al., 2019. Oral
administration of compound probiotics ameliorates HFD-induced gut microbe
dysbiosis and chronic metabolic inflammation via the G protein-coupled re-
ceptor 43 in non-alcoholic fatty liver disease rats. Probiotics and Antimicrobial
Proteins 11(1):175e185.
[73] Duarte, S.M.B., Stefano, J.T., Miele, L., Ponziani, F.R., Souza-Basqueira, M.,
Okada, L., et al., 2018. Gut microbiome composition in lean patients with
NASH is associated with liver damage independent of caloric intake: a pro-
spective pilot study. Nutrition, Metabolism, and Cardiovascular Diseases 28(4):
369e384.
[74] Younes, R., Bugianesi, E., 2019. NASH in lean individuals. Seminars in Liver
Disease 39(1):86e95.MOLECULAR METABOLISM 35 (2020) 100954  2020 The Author(s). Published by Elsevier GmbH. This is an open
www.molecularmetabolism.com[75] Hosseini, E., Grootaert, C., Verstraete, W., Van de Wiele, T., 2011. Propionate
as a health-promoting microbial metabolite in the human gut. Nutrition Re-
views 69(5):245e258.
[76] Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P.K., Cazanave, S., et al.,
2018. The presence and severity of nonalcoholic steatohepatitis is associated
with specific changes in circulating bile acids. Hepatology 67(2):534e548.
[77] Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K.,
et al., 2013. Gut microbiota regulates bile acid metabolism by reducing the
levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell
Metabolism 17(2):225e235.
[78] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R.,
et al., 2009. Increased intestinal permeability and tight junction alterations
in nonalcoholic fatty liver disease. Hepatology 49(6):1877e1887.
[79] Medgyesi, D., Hobeika, E., Biesen, R., Kollert, F., Taddeo, A., Voll, R.E., et al.,
2014. The protein tyrosine phosphatase PTP1B is a negative regulator of CD40
and BAFF-R signaling and controls B cell autoimmunity. Journal of Experi-
mental Medicine 211(3):427e440.
[80] Farrell, G.C., van Rooyen, D., Gan, L., Chitturi, S., 2012. NASH is an inflam-
matory disorder: pathogenic, prognostic and therapeutic implications. Gut and
Liver 6(2):149e171.
[81] Moran, G.W., O’Neill, C., McLaughlin, J.T., 2012. GLP-2 enhances barrier
formation and attenuates TNFalpha-induced changes in a Caco-2 cell model of
the intestinal barrier. Regulatory Peptides 178(1e3):95e101.
[82] Keller, J., Binnewies, U., Rosch, M., Juul Holst, J., Beglinger, C.,
Andresen, V., et al., 2015. Gastric emptying and disease activity in in-
flammatory bowel disease. European Journal of Clinical Investigation
45(12):1234e1242.
[83] Bernsmeier, C., Meyer-Gerspach, A.C., Blaser, L.S., Jeker, L., Steinert, R.E.,
Heim, M.H., et al., 2014. Glucose-induced glucagon-like Peptide 1 secretion is
deficient in patients with non-alcoholic fatty liver disease. PloS One 9(1):e87488.
[84] Klaman, L.D., Boss, O., Peroni, O.D., Kim, J.K., Martino, J.L., Zabolotny, J.M.,
et al., 2000. Increased energy expenditure, decreased adiposity, and tissue-
specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice.
Molecular and Cellular Biology 20(15):5479e5489.
[85] Park, M.K., 2016. Glucagon-like peptide-2. Sub[chapter 17]D. In: Takei, Y.,
Ando, H., Tsutsui, K. (Eds.), Handbook of hormones. San Diego: Academic
Press, p. 138-e17D-5.
[86] Kushner, J.A., Haj, F.G., Klaman, L.D., Dow, M.A., Kahn, B.B., Neel, B.G.,
et al., 2004. Islet-sparing effects of protein tyrosine phosphatase-1b deficiency
delays onset of diabetes in IRS2 knockout mice. Diabetes 53(1):61e66.
[87] Charlton, M., Ahlman, B., Nair, K.S., 2000. The effect of insulin on human
small intestinal mucosal protein synthesis. Gastroenterology 118(2):299e
306.access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 19
